The initial reporter received questionable (b)(6) elecsys syphilis results for one patient from cobas 8000 cobas e 602 module serial number (b)(4).The patient information was provided as "multiparous female ((b)(6)) with a history of substance abuse and complicated social history".The patient presented at another facility at (b)(6) gestation with early labor and premature rupture of membranes.The patient had blood work, received betamethasone as well as iv penicillin, and was then transferred to this facility for high risk pregnancy care.On (b)(6) 2019, the syphilis eia result from this other facility was (b)(6) (biorad bioplex).The results from the blood work at the first facility were not provided to this facility.Therefore, the patient had new blood work performed including pre-natal screening blood tests.On (b)(6) 2019, the elecsys syphilis eia result from the cobas e602 was (b)(6).A urine toxicology screen was positive for cocaine and the patient had a history of recent cocaine use.The patient noted taking ibuprofen and smoking cigarettes but no other medications or supplement history.The patient received betamethasone as well as iv ampicillin and erythromycin as per protocol for premature rupture of membranes.The patient¿s contractions ceased and she remained at this facility from (b)(6) 2019 whereupon she was transferred back to the first facility at her request.On (b)(6) 2019, the syphilis eia result from the other facility was (b)(6) (biorad bioplex).On (b)(6) 2019, a frozen aliquot of the (b)(6) 2019 sample was retested and the result from the cobas e602 was (b)(6).At the other facility, the repeat result for this same sample was (b)(6) (biorad bioplex).There was no allegation of an adverse event.
|